RAPTIVA (efalizumab)
[back] Drug list  [back] Genentech  [back] Withdrawn drugs

[Generically known as efalizumab, Raptiva is an injectable medication used in the treatment of psoriasis. To reduce the presence of psoriasis plaques, Raptiva medication suppresses the immune system and prevents white blood cells from making their way into the skin's tissues. The Raptiva drug is produced by Genentech and Merck SeronoGenentech recently agreed to withdraw all of the Raptiva on the U.S. market, based on the viral infections diagnosed in Raptiva patients in America and around the world.1.]

See: Drug induced leukoencephalopathy, meningitis, viral infections

Raptiva Attorney  Despite its effectiveness at reducing psoriasis plaques, Raptiva is currently known to cause a variety of serious, potentially fatal infections, including: bacterial sepsis, invasive fungal disease, progressive multifocal leukoencephalopathy (PML), viral meningitis

Raptiva Deaths  Raptiva deaths have been reported by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, the FDA's counterpart for the EU (European Union). The Raptiva deaths were apparently due to PML (progressive multifocal leukoencephalopathy), a devastating and rare brain infection.

Defective Drugs: adrugrecall.com